
    
      Upon providing written informed consent, subject will be screened in the study and assessment
      will be performed at that time such as safety laboratory assessments, physical examination,
      vital sign, medical history taking, 24 hours pain intensity score, EQ-5D, pain and sleep
      questionnaire, physician's overall satisfaction and subject's overall satisfaction.

      If patient is eligible in inclusion/exclusion criteria at the time of visit 1, the patient
      will receive treatment with NORSPAN®.

      Treatment with NORSPAN® will be started from 5 μg/h (1 patch a week) for 2 weeks, and proper
      titration (up-titration) will be allowed at visit 2(wk 2) and at visit 3(wk 4) according to
      the investigator's decision.
    
  